Vorhandelsmarkt: 1.04 -0.03 -2.80%

An 2 Therapeutics Inc (ANTX)

An 2 Therapeutics Inc Aktie (ANTX) Neueste Nachrichten

An 2 Therapeutics Inc (ANTX)

An 2 Therapeutics Inc Aktie (ANTX) Neueste Nachrichten

Araris Doubles Down With Dual-payload ADC - BioProcess Online

Black Diamond Therapeutics Announces Initial Phase 2 Data - GlobeNewswire

Ildikó Enyedi working on her new feature, Silent Friend - Cineuropa

Boss Brown calls on Ayr players to step up after losing top scorer for season - Ayr Advertiser

Black Diamond Therapeutics to Host Webcast Presentation of - GlobeNewswire

Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC - Yahoo Finance

Scott Brown admits Anton Dowds injury is huge blow for Ayr United as he challenges others to step up - Daily Record

Adicet Bio shares hold neutral rating amid positive study data By Investing.com - Investing.com South Africa

Adicet Bio reports promising ADI-001 therapy data - Investing.com

Australia's Amplia Therapeutics rises as US FDA fast-tracks cancer drug - XM

Applied Therapeutics: AdCom Decision Takes Govorestat Approval A Step Closer (NASDAQ:APLT) - Seeking Alpha

Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) - Business Wire

Agatha All Along Episode 2 Cast & Characters Guide (Photos) - The Direct

Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 - GlobeNewswire

Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of Neurological Surgeons Annual Meeting - Yahoo Finance

VERV CLASS ACTION: Verve Therapeutics, Inc. Stockholders - GlobeNewswire

IVIEW Therapeutics Inc. Completes Patient Recruitment for Phase 1/2 Trial of IVW-1001 Ophthalmic Eyelid Wipe in Dry Eye Disease Patients - PR Newswire

IVIEW Therapeutics Inc. Completes Patient Recruitment for Phase 1/2 Trial of IVW-1001 Ophthalmic Eyelid Wipe in Dry Eye Disease Patients - Yahoo Finance

Nanoscope Therapeutics Announces End-of-Phase 2 Meeting with U.S. FDA and Plan to Initiate a Phase 3 Clinical Trial of MCO-010 to Treat Stargardt Macular Degeneration - PR Newswire

Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting - GlobeNewswire

Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting - Yahoo Finance

Allarity Therapeutics Takes Decisive Step Toward Regaining Nasdaq Compliance with Nasdaq Listing Rule 5550(a)(2) - GlobeNewswire

Allarity Therapeutics Takes Decisive Step Toward Regaining Nasdaq Compliance with Nasdaq Listing Rule 5550(a)(2) - Yahoo Finance

Keros Therapeutics Announces Update on Enrollment in the Phase 2 TROPOS Trial - GlobeNewswire

Keros Therapeutics Announces Update on Enrollment in the Phase 2 TROPOS Trial - Yahoo Finance

Dyne Therapeutics Announces New Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented Dystrophin Expression and Functional Improvement in Multiple Cohorts - Yahoo Finance

Soleno Therapeutics: 2 New Catalysts To Bring Forth Change For PWS Patients (SLNO) - Seeking Alpha

Innovo Therapeutics Inc. Announces Phase 2 Clinical Results Demonstrating the Innovative Efficacy of INV-001 for the Treatment of Post-thyroidectomy Scars - Winchester Herald Chronicle

Director J Singleton Sells 5,700 Shares of Viking Therapeutics Inc (VKTX) - Yahoo Finance

Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease - Yahoo Finance

Innovo Therapeutics Inc. Announces Phase 2 Clinical Results Demonstrating the Innovative Efficacy of INV-001 for the Treatment of Post-thyroidectomy Scars - Manchestertimes

Innovo Therapeutics Inc. Announces Phase 2 Clinical Results Demonstrating the Innovative Efficacy of INV-001 for the Treatment of Post-thyroidectomy Scars - Business Wire

iTeos Therapeutics Announces Late-Breaking Oral - GlobeNewswire

iTeos Therapeutics Announces Late-Breaking Oral Presentation of Phase 2 GALAXIES Lung-201 Interim Data at the European Society for Medical Oncology Congress 2024 - Yahoo Finance

Scorpion Therapeutics to Present STX-478 Initial Phase 1/2 Data at ESMO Congress 2024 - Business Wire

Why Is Viking Therapeutics, Inc. (VKTX) the Best Diabetes Stock to Buy Now? - Yahoo Finance

Are Medical Stocks Lagging Acrivon Therapeutics, Inc. (ACRV) This Year? - Yahoo Finance

Tempest Announces Successful End-of-Phase 2 Meeting with - GlobeNewswire

Viracta Therapeutics Announces Positive Data from the Phase - GlobeNewswire

AN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung Disease - Business Wire

Intellia Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress - GlobeNewswire

Tonix Pharmaceuticals Announces Publication in Microorganisms of Technology that Expands Company’s Capabilities in Generating Potential Therapeutic Fully Human Antibodies Against SARS-CoV-2 and Other Pathogens - Yahoo Finance

Travere Therapeutics, Inc. (TVTX) Q2 2024 Earnings Call Transcript - Seeking Alpha

OVID Investors Have Opportunity to Join Ovid Therapeutics Inc. Fraud Investigation with the Schall Law Firm - Morningstar

Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-3001 for the Treatment of Alpha-1 Antitrypsin Deficiency - GlobeNewswire

Cognition Therapeutics, Inc?s Proof-of-Concept Phase 2 SHINE Trial Demonstrates Consistent Improvement in Cognitive Outcomes with Once-Daily Oral CT1812 in Mild-to-Moderate Alzheimer?s Patients - Marketscreener.com

Cognition Therapeutics’ Proof-of-Concept Phase 2 SHINE - GlobeNewswire

Cognition Therapeutics to Host Investor Webcast to Discuss - GlobeNewswire

CytoMed Therapeutics (NASDAQ:GDTC) Trading Down 2% - Defense World

Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED) - Business Wire

Viking Therapeutics, Inc. (VKTX) Q2 2024 Earnings Call Transcript - Seeking Alpha

Viking Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update - PR Newswire

Galectin Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying - Benzinga

Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor - Biogen | Investor Relations

Virios Therapeutics, Inc. Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne Center - Marketscreener.com

Virios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne Center - Yahoo Finance

Atossa Therapeutics Completes Enrollment of 80mg Pharmacokinetic Run-In Cohort in Phase 2 ... - WDRB

Allarity Therapeutics Outlines Company’s 2024 Progress and Objectives - GlobeNewswire

4D Molecular Therapeutics: Yesterday's Wet-AMD Data Given Thumbs Down By Market - Seeking Alpha

4D Molecular Therapeutics falls 30% following phase 2 wet AMD candidate data - Seeking Alpha

Lexeo Therapeutics Announces Positive Interim Phase 1/2 - GlobeNewswire

Lexeo Therapeutics Announces Investor Webcast to Report Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy on Monday, July 15, 2024 - Yahoo Finance

Kazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma - Yahoo Finance

Intensity Therapeutics, Inc. Announces First Patie | Newswise - Newswise

Kymera Therapeutics Shares Climb on Sanofi's Plan to Expand Phase 2 Trials - MarketWatch

Cartesian Therapeutics Secures $130 Million in PIPE Financing Amid Announcement of First Patient Dosed in Phase 2 Trial for mRNA Cell Therapy - BioBuzz

Results from Cognition Therapeutics’ Phase 2 SHINE Study of - GlobeNewswire

Results from Cognition Therapeutics' Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer's Disease ... - Yahoo Finance

Cartesian Therapeutics Announces First Patient Dosed in Phase 2 Trial of Descartes-08 in Systematic Lupus Erythematosus - Yahoo Finance

Ähnlich wie ANTX